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Background: Opiate substitution treatment (OST) is the most widely used treatment for opioid dependence in
Germany with substantial long-term benefits for the patient and for society. Due to lessened restrictive admission
criteria, the number of registered OST patients in Germany has increased continuously in the recent years, whereas
the number of physicians providing OST has remained constant. Previous data already indicated a deteriorating
situation in the availability or quality of OST delivered and that structural barriers impede physicians in actively
providing OST. The present survey among a sample of primary care physicians in Germany aimed to identify and
assess potential structural barriers for the provision of health care in the context of OST.
Methods: An anonymous written questionnaire was sent out to a sample of 2,332 physicians across Germany
providing OST. Physicians contacted were identified through databases of the Federal State Chambers of Physicians
and/or of the Federal Associations of Statutory Health Insurance Physicians. Data obtained were analysed descriptively.
Results: The response rate was 25,5% and the majority of 596 physicians sampled viewed substantial problems in
terms of the regulatory framework of OST care in the German context. Furthermore, financial remuneration, insufficient
qualification, as well as inadequate interdisciplinary cooperation in the treatment of comorbidities of opiate substituted
patients were regarded as problematic. The number of physicians providing OST in Germany is expected to substantially
decrease in the near future.
Conclusion: Despite less restrictive admission criteria for OST in Germany, the legal regulation framework for OST is still
a limiting factor through raising concerns on the provider and consumer side to be unable to adhere to the strict rules.
To avoid future shortages in the provision of OST care on the system level in Germany, revisions to the legal framework
seem to be necessary. In regards to adequate care for drug use-related infectious diseases and psychiatric comorbidities
commonly found in opiate substituted patients, efforts are required to improve professional qualifications of physicians
providing OST as well as respective interdisciplinary collaboration.
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The effectiveness of opiate substitution treatment (OST)
and its substantial long-term benefits for patient and so-
ciety in the treatment of opioid dependence are well docu-
mented. OST, e.g. with methadone or buprenorphine,
improves the patients’ health and reduces illicit opiate use,
decreases the risk of infections with blood-borne viruses,
and reduces overdose-related deaths [1-6]. Recently, com-
parable findings were also shown for Germany [7,8].
Current prevalence estimations based on treatment, police
and drug-related death data from 2011 suggest a popula-
tion of up to 174,000 problem opiate users in Germany
[9]. Heroin is the predominant opiate abused and nearby
all problem opiate users are heroin users.
In Germany, OST is mainly delivered by office based
GPs, in conjunction with community-based pharmacies;
some OST delivery also occurs in specialized addiction
clinics. In community-based treatment, the regulatory
framework allows for take-home doses of up to seven
days [10]. OST is considered the first-line treatment for
severe chronic opioid dependence and its ultimate goal
of OST in Germany is opioid abstinence [10]. To achieve
this, the German OST concept includes protection of
the patient’s health and social stabilization. The key2607 2616 2664 2706
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OST in the period 2003–2012.inclusion criterion for OST is a main diagnosis of opiate
dependence according to ICD-10. To qualify for the
provision of OST in Germany, a physician has to meet
specific qualification requirements for addiction therapy.
OST physicians have to register each patient at the Fed-
eral Narcotics Control Board (Bundesopiumstelle) and
are obliged to document all relevant patient and treat-
ment data (e.g. diagnoses, psychosocial counselling, fre-
quencies and results of drug screenings and supervisions
of additional use of psychotropic substances) [10]. In the
past, violations against the German regulations by OST
physicians resulted in prosecutions and/or occupational
consequences like fines, suspended sentences and revo-
cations of the medical license.
OST is the most widely used treatment for opioid de-
pendence in Germany. The number of registered OST
patients increased by almost 44% - from 52.700 to 75.400 –
between 2003 and 2012 (Figure 1) [11]. Similarly, the
number of physicians certified for OST increased continu-
ously from 5.148 in 2003 to 8.416 in 2012 [11]. The num-
ber of physicians actively providing OST care, however,
has remained broadly constant (from N= 2,607 in 2003 to
N = 2.731 in 2012) (Figure 1). In 2012, less than one third
of the licensed physicians were providing OST. As a2673 2700 2710 2703 2731
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vider increased from 20 in 2003 to more than 27 in 2012.
Previous data indicate that current German regula-
tions do not stimulate physicians to engage in OST
[12-15]. In particular, the strict legal requirements of the
German Narcotics Act (Betäubungsmittelgesetz, BtMG)
and the respective regulations for the prescription of
narcotics are regarded as a major structural barrier
[12-15]. Especially the integration of the German Nar-
cotics Act in the penal law constitutes a main reason for
a legal uncertainty for providers [14]. In a pilot survey,
we had already identified further structural barriers for
the provision of OST in Germany, such as insufficient
remuneration, inadequate availability of psychosocial
support and lack of interdisciplinary cooperation in the
treatment of drug-related infectious diseases and psychi-
atric comorbidities [14]. One fifth of the physicians were
dissatisfied with the current OST conditions, while virtu-
ally everybody saw need for improvement [14]. These
findings corroborated the outcomes of a national survey
including representatives of the state chambers of physi-
cians from all sixteen states in Germany, which repre-
sent the interests of physicians in terms of professional
policy and legislative procedures. Six of them stated that
the overall conditions for the provision of OST have de-
teriorated in recent years. As a consequence, five cham-
bers regarded the regional provision of OST in some
rural areas as already considerably inadequate or insuffi-
cient [12]. This reflected the findings of a more recent
survey, which showed that access to OST was deemed
inadequate by opiate users in and out of treatment, as
well as by current and former OST prescribers, espe-
cially outside of major cities [15].
Similar to a number of other countries, the prevalence
of psychiatric and somatic comorbidities, especially drug
related infectious diseases, among opiate addicts is high in
Germany [16]. Therefore, OST in Germany is regarded as
an integral health care model including also medical care
for drug related infectious diseases and psychiatric
comorbidities. Hence, a deteriorating situation in the avail-
ability or quality of OST provision would undermine the
objectives of standards as defined in the German OST
regulations.
In order to better understand the current landscape of,
and understand key factors for future OST provision,
the principal aim of this survey therefore was to identify
and assess potential structural barriers for the provision
of OST and the medical care for drug-related infectious
diseases and psychiatric comorbidities in context of OST
in Germany.
Methods
In March 2009, an anonymous questionnaire was sent
out to a sample of 2,332 OST physicians registered indatabases of the Federal State Chambers of Physicians
and/or of the Federal Associations of Statutory Health
Insurance Physicians. The questionnaire covered per-
sonal and care setting characteristics, such as medical
specialisation, medical experience, size and location of
the medical practice environment, professional long-
term prospects (e.g. career planning, expected time until
retirement) and treatment standards in regard to the tar-
get population (i.e., opioid dependent patients). Further
question items focused on barriers encountered in the
provision of health care for opiate addicts and on rec-
ommendations to improve the current OST situation.
We used closed-ended question items to assess previ-
ously identified structural barriers. For instance, regard-
ing to structural barriers for OST, we asked: “Please rate
to which extent the following aspects hinder your daily
work in OST: (A) Strong degree of regulation; (B) High
interdisciplinary requirements; (C) Legal consequences
by violation of regulations; (D) Disproportion between
effort & remuneration; (E) Inadequate psychosocial sup-
port”. Such items had to be rated on a 5-point-Likert-
scale from, “strongly disagree” to, “strongly agree”.
Open-ended question items were used to identify fur-
ther possible structural barriers and to assess their im-
pact on the provision of OST. Free text fields were used
for physician suggestions to improve the current OST
care situation (e.g. “What opportunities do you see to im-
prove the current situation of OST care in your region?”).
Ratings of the regional medical treatment situation for
opiate addicts were assessed using a 6-point-Likert-scale
following the German academic grading system (from
“1 = very good” to “6 = totally deficient”). Subgroup ana-
lyses were conducted based on the following categories:
size of treatment unit‘(small = up to 10 substitution cli-
ents per year; medium= 11 to 40 substitution clients
per year; large =more than 40 treatment cases per year)
and, “practice localisation” (urban area = more than
20,000 population size vs. rural area = 20,000 or less).
Open item responses were coded and categorised manu-
ally based on thematic analysis; descriptive statistical ana-
lyses of quantitative data were performed using SPSS,
version 18.0. Group comparisons were conducted using
either Pearsons chi-squared tests (Fisher’s exact test if
more than 20% of expected cell sizes were smaller than
five), independent sample t-tests or one-way ANOVAs,
depending on scale levels and number of groups to be
compared. P-values smaller than .05 were considered sta-
tistically significant.
Results
Characteristics of the responding physicians and their
treatment facilities
596 physicians (response rate: 25.5%) with a mean ex-
perience in OST of 12.3 years (± 5.67) completed and
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higher percentage of general practitioners provided OST
as compared to psychiatrists (83.7% vs. 8.1%; Table 1).
Compared to treatment facilities in rural areas, facilities
in urban locations showed a higher grade of interdiscip-
linary specialisation: The urban subsample (n = 408)
comprised 68% respondents from general practices, 13%
from interdisciplinary group practices, 9% were spe-
cialised in internal medicine, 7% were psychiatrists, andTable 1 Health care setting and service characteristics of stud
unit size
Item Total (N = 596
Treatment unit characteristics
Single practice* 54.0
Urban* 68.5
Number of medical practitioners per practice** 1.8 (±1.4)
Practices with at least one psychologist or social worker* 10.1
Total number of employees (including nurses, etc.)** 5.7 (±3.7)
Addiction society member* 23.3
Medical specialisation* (multiple answers)
General practitioner 83.7
Internal medicine 19.6
Psychiatry 8.1
Additional qualifications*
Infectiology 3.2
Psychotherapy 4.4
Opiate substitution treatment (OST)
Number of patients in OST** 56.4 (±75.0)
Physicians’ years in OST** 12.4 (±5.7)
Assessment of regional OST care situationG 3.5 (±1.5)
Deficient regional OST care situation*** 27.4
Infectious diseases (HCV/HIV)
Regular HIV/HCV Testing* 69.1
Provide HIV treatment*** 25.4
Provide HCV treatment*** 51.7
Assessment of regional HCV/HIV care situation
for OST patientsG
2.9 (±1.4)
Deficient regional HCV/HIV care situation*** 15.3
Psychiatric co-morbidities
Estimated percentage of OST patients with
psychiatric comorbidity**
34.9 (±26.9)
Treatment of psychiatric co-morbidities always/often*** 64.5
Treatment of psychiatric co-morbidities always/often
w/o psychiatrist*** (n = 544)
61.4
SAccording to number of OST clients/year: small = up to 10; medium = 11 to 40; large
GMean values ± SD of ratings from 1 = very good to 6 = totally deficient.
* Percentages; ** Mean ± SD; *** yes, percentages.3% had other medical specialisations (e.g. gynecologists).
The subsample from rural areas (n = 187) comprised
81% general practitioners, 10% from interdisciplinary
group practices, 5% internists, 3% psychiatrists and 2%
others; χ2 (4, n = 595) = 11.08, p = .026. Small treatment
units seem to be more common in rural areas, whereas
over 80% of the large substitution treatment centres
were located in urban areas; χ2 (2, n = 595) = 41.769,
p < .001 (Table 1).y physician participants, total sample and by treatment
) Treatment unit sizeS Group
differenceSmall (N = 130) Medium (N = 209) Large (N = 257)
60.8 53.6 51.0 p = .003
49.2 65.4 80.9 p < .001
1.6 (±0.9) 1.7 (±1.8) 1.9 (±1.1) n.s.
3.1 2.9 19.5 p < .001
4.7 (±2.5) 5.3 (±3.5) 6.7 (±4.2) p < .001
4.6 16.7 38.1 p < .001
86.9 83.7 82.1 n.s.
20.8 18.7 19.8 n.s.
4.6 3.3 13.6 p < .001
0.8 1.4 5.8 p = .006
4.6 2.9 5.4 n.s.
5.0 (±3.3) 26.6 (±8.9) 106.6 (±91.7) p < .001
9.4 (±6.0) 13.1 (±5.3) 13.4 (±5.4) p < .001
3.8 (±1.5) 3.5 (±1.4) 3.4 (±1.5) p = .037
34.4 27.5 23.8 n.s.
54.7 72.6 79.8 p < .001
16.1 23.5 31.1 p = .006
32.8 49.3 62.9 p < .001
2.8 (±1.4) 2.8 (±1.3) 3.0 (±1.4) n.s.
13.7 11.7 19.0 n.s.
37.3 (±33.4) 32.4 (±23.5) 35.9 (±26.2) n.s.
55.9 58.4 73.8 p < .001
53.7 56.9 69.7 p = .004
= more than 40.
Schulte et al. Substance Abuse Treatment, Prevention, and Policy 2013, 8:26 Page 5 of 10
http://www.substanceabusepolicy.com/content/8/1/26Opiate substitution treatment
The patient sample sizes to whom OST was provided in
the treatment facilities represented by the responding
physicians averaged 56.2 (±75.0) cases per year (Table 1);
with 68.4 (±85.1) in urban facilities and 30.5 (±34.0) in
rural treatment units; t (584.6) = −7.737, p < .001. The
overall quality situation of OST provision was rated 3.5
(± 1.45) on a scale from 1 (very good) to 6 (totally defi-
cient); overall quality was rated better by respondents
based in urban locations: 3.3 ±1.4 urban vs. 3.9, ±1.5
rural; t (588) = 4.606, p < .001. One third of physicians
working in rural areas rated the situation as “deficient”
or “totally deficient”; less than 20% of this subgroup
assessed the provision of OST in their region as “good”
or “very good” (Figure 2).
More than 80% of respondents assessed the high level
of OST regulations in conjunction with extensive admin-
istrative requirements as the main structural barriers,
which “often” or “very often” complicated the daily work
in OST (Table 2). Three out of four physicians regarded
the financial remuneration as insufficient. Nearly 80%
regarded the possible legal consequences in case of vio-
lation of OST regulations as inappropriate. Almost half
of the physicians working in small OST facilities, as well
as those in rural areas, perceived the regional availability
of psychosocial support related to OST care to be inad-
equate. One third of the physician sample surveyed will
retire – i.e. suspend their OST care activities - within the
next 8 years.
62.4% of our sample (n = 372) provided narrative sug-
gestions for improvement of current conditions of OST
care. The most predominant suggestions consisted of re-
ducing bureaucracy and administrative responsibilities
(25% of respondents), reducing legal barriers (20%) and44.3%
18.0%
43.5%
33.7%
(very) good acceptable
Figure 2 Assessment of regional OST care situation by OST physicianimproving the financial reimbursement (20%), which is
in accordance with the identified structural barriers
(Figure 3). Moreover, an overall higher number of OST
prescribers considered improved cooperation and net-
working (13%) as important, and also the issues of the
social acceptance and stigmatization of opioid addiction
and/or OST were raised (7%). Other suggestions in-
cluded the reduction of take-home regulations (3%) or
increase/improvement of training programs (3%).Drug-related infectious diseases
One out of four treatment facilities surveyed offered
antiretroviral treatment for human immunodeficiency
virus (HIV) infections and half of the OST facilities of-
fered antiviral hepatitis C (HCV) -therapy. On average,
respondents assessed the overall situation for HIV/HCV
care to be sufficient in their region; one in seven rated
the situation as deficient. Insufficient professional ex-
perience and medical qualification were found to be
main structural barriers in provision of HIV/HCV treat-
ment care (Table 2). Further obstacles to providing HIV/
HCV treatment care included limited financial compen-
sation and the perceived risks and side effects of treat-
ment. Accordingly, ways to increase the number of
HCV/HIV treatments (selection from a list in the survey,
multiple answers allowed) were seen as including a more
adequate framework of financial reimbursement (HCV:
40.4%, HIV: 36.6%), designated HIV/HCV care education
for physicians (HCV: 35.4%, HIV: 35.4%), and improved
cooperation with HIV/HCV specialists (HCV: 32.7%,
HIV: 30,7%). One in four physician respondents (26.0%)
intended to withdraw from HCV/HIV treatment provision
due to the above-mentioned barriers.37.7%
22.9%
(totally) deficient
rural areas
urban areas
s working in rural or urban areas.
Table 2 Structural barriers in the health care provision for substituted opiate addicts
Items All (N = 596) Treatment unit sizeS Group
differenceSmall (N = 130) Medium (N = 209) Large (n = 257)
Main barriers for OST (%; yes, often)
Strong degree of regulation 84.8 82.3 88.0 83.5 n.s.
High interdisciplinary requirements 29.7 24.6 32.7 29.8 n.s.
Legal consequences by violation of regulations 79.1 74.6 81.7 79,2 n.s.
Disproportion between effort & remuneration 75.0 76.9 80.3 69.8 p = .030
Inadequate psychosocial support 37.9 46.2 37.5 34.1 n.s.
Main barriers for HIV treatment (%; yes, often)
Insufficient experience/qualification 59.7 58.5 64.1 56.8 n.s.
High treatment risks 26.3 26.2 29.2 24.1 n.s.
Budgetary reasons 29.9 35.4 31.6 25.7 n.s.
Lack of cooperation with regional experts 12.4 17.7 10.5 11.3 n.s.
Difficulties to integrate treatment in the daily routines 19.5 18.5 23.9 16.3 n.s.
Main barriers for HCV treatment (%; yes, often)
Insufficient experience/qualification 34.2 39.2 39.7 27.2 p = .007
High treatment risks 19.5 20.8 21.5 17.1 n.s.
Budgetary reasons 23.7 28.5 28.2 17.5 p = .009
Lack of cooperation with regional experts 6.9 12.3 5.7 5.1 p = .021
Difficulties to integrate treatment in the daily routines 15.9 13.8 20.1 13.6 n.s.
Main barrier for psychiatric care (%; yes, often)
Insufficient capacity to refer OST patients to psychiatrists 42.3 31.0 46.9 44.3 p = .012
SAccording to number of OST clients/year: small = up to 10; medium = 11 to 40; large = more than 40.
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A minority of OST physicians was trained as psychia-
trists (Table 1), and one third of OST physicians (exclud-
ing psychiatrists) observed insufficient capacities in their
regions for psychiatric referrals for OST patients. Conse-
quentially, a high percentage of physicians without spe-
cialist training in psychiatry are treating psychiatric
comorbidities in their OST patients. One in fourteen
physicians considered cooperation with psychiatrist spe-
cialists to be adequate. Accordingly, the physician re-
spondents suggested improving the local cooperation
between psychiatrists and OST care providing physi-
cians, increasing the number of psychiatrist specialists
and implementing advanced training for psychiatrists in
addiction medicine in the interest of an overall improve-
ment of psychiatric care in OST. A further suggestion
focused on an expanded availability of specialised psy-
chiatric outpatient clinics as potential remedies for the
observed deficits in psychiatric care. Only 1 out of 20 re-
spondents did not see any need to improve the current
psychiatric care situation for their patients.
Discussion
This survey reviewed the practices and attitudes of phy-
sicians with longstanding experience in the provision ofOST regarding the current status of health care for opi-
ate addicts in their region, the impact of structural barriers
on the provision of OST as well as medical care for drug-
related infectious diseases and psychiatric comorbidities in
Germany.
The majority of the sample agreed that different struc-
tural barriers currently hinder the provision of OST. In
accordance with previous studies, the strict legal regula-
tions of OST in combination with complex documenta-
tion requirements were identified as central obstacles
[12,14,15]. Considering the empirical evidence of the ef-
fectiveness of OST [8] and the high number of OST pa-
tients enrolled in treatment in Germany [11] it can be
assumed that the majority of treatment episodes occur
without any major medical and legal problems. Hence,
the extensive administrative requirements to meet the
regulation requirements for the therapeutic use of OST
medications – especially when compared to much more
liberal approaches for other controlled medical sub-
stances or interventions - has to be questioned.
The highly complex German OST regulations are
resulting in a legal uncertainty for OST providers, espe-
cially as several cases of violations have resulted in se-
verely punitive consequences in their adjudications
recently. No other medical field features legal regulations
7.0%
8.6%
9.9%
13.4%
18.8%
19.9%
20.2%
25.0%
Higher acceptance / less stigmatiszation
More regional practices / decentralisation
Improvement of psychosocial support
Better networking/ cooperation
Higher number of practices/ OST prescribers
Better financial reimbursement
Reduction of legal barriers
Reduction of bureaucracy and administration
Figure 3 Categories of suggestions from OST physicians to improve the current OST care situation in Germany. Percentage of respondents,
multiple suggestions were possible.
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case of violations - as the field of OST. This might also
be due to the historical development of OST regulations,
which initially were based on the assumption that (opi-
ate) addiction is a “criminal condition” and addicts are
“morally inferior deviants” [17,18], resulting in compul-
sory, strict abstinence oriented treatment models.
Today, addiction is defined as a chronic, relapsing
brain disease and addiction medicine and addiction re-
search are more or less accepted professional medical
specialties [19]. Based on this “medical paradigm” for
opiate addiction treatment, the German regulations for
OST have been revised several times in the last two de-
cades. Especially, the revisions of minimum treatment
admission requirements resulted in a substantive quanti-
tative expansion of OST during this period. However,
the limiting factor ‘OST regulations’ is still existing; physi-
cians and patients are still concerned to be unable to ad-
here to the strict rules, which consequently impedes
physicians to provide OST. This also raises the question of
whether the primarily result-oriented (‘abstinence’) OST
regulations deflect from the aim of health improvement,
as they tangibly function as process-oriented obstacles.
The current OST regulations also seem to be a reason
for the frequent responses suggesting that the financial
remuneration for OST is inadequate. For instance, the
regulations for opiate prescriptions in the context of
OST usually require a weekly physician-patient consult-
ation, while the Uniform Evaluation Scale (EBM), thecompensation system of outpatient health care in
Germany, only reimburses four consultations per quarter
[12]. Furthermore, although OST should result in a sub-
stantial improvement and stabilization of the patient’s
medical condition, the EBM only provides for a lump sum
compensation per OST patient without additional com-
pensation for the potential treatment of comorbidities.
Nevertheless, most OST prescribers in our study sam-
ple indicated that they provide comprehensive general
medical care to their patients; for example, half of the
prescribers offered pharmacotherapeutic HCV treat-
ment, a rate that can be considered rather high in com-
parison with international standards. However, one third
of the physicians surveyed felt insufficiently qualified to
deliver more extensive HCV and/or HIV treatment. This
might be reasonable, as the increased complexity of the
current pharmacotherapeutic treatment regimens for
these infectious diseases require specific medical expert-
ise, which may exceed the medical qualifications and
skills of GPs. In order to meet qualifications for
provision of treatment for infectious diseases within the
context of OST care, continuous specific medical educa-
tion and intensified collaborations with regional special-
ists should be required [20]. Tailored approaches can
optimise the HCV/HIV therapy for opiate addicts in pri-
mary care, e.g. integrated HCV/HIV care models
[21-24]. A prerequisite for enhanced HCV/HIV care is
regular screening and testing for infectious diseases
among opiate dependent patients. In our sample, only
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titis C testing. Only 55% of those in the small treatment
clinics offered this basic assessment, also suggesting that
the adherence to the existing German clinical practice
guidelines on the management of HCV infection is not
optimal. In this guideline a regular HCV testing of every
12 months is required for OST patients without a previ-
ously diagnosed chronic HCV infection [25]. Targeted
strategies to improve implementation of clinical practice
guidelines might be helpful to increase related awareness
among OST physicians [26,27].
The minority of OST physicians in Germany are
specialised in psychiatry [14,15,28,29]. Given the high
prevalence of psychiatric comorbidities among OST pa-
tients, a timely and continuous diagnostic and thera-
peutic psychiatric care plays a crucial role in this
population yet cannot be covered solely by non-
psychiatrist OST physicians [8]. The German health care
system is not geared towards the high rates of - commonly
complex - psychiatric comorbidities in OST patients, as
also a successful treatment of substance-related disorders
are required before psychiatric comorbidity care can be
provided, often resulting in ‘revolving door’ dynamics be-
tween OST and psychiatric care. Furthermore, due to an
increasing demand for psychiatric care in Germany, there
is a general lack of psychiatric capacity in private practices
and long waiting lists exist in some regions. Considering
the high number of patients treated by non-psychiatrist
physicians and the lack of referral options to psychiatrists,
regional efforts for more psychiatric training of OST phy-
sicians and a closer cooperation with the psychiatric care
sector should be established. This is also relevant in regard
to the treatment of (psychiatric) side-effects in pharma-
cotherapeutic HIV and HCV therapies [30,31]. In turn, a
closer cooperation between OST physicians and psychia-
trists might therefore also result in an increased uptake of
HCV/HIV treatments.
Another structural obstacle concerns the insufficient
availability of OST-related psychosocial services, i.e. in
rural regions. According to the new directives of the
Federal Medical Council, the provision of psychosocial
treatment and support remains a prerequisite for the
provision of OST, but type and extent of care can vary
according to patient needs [32]. This case-by-case deci-
sion might result in a more effective allocation of psy-
chosocial care and might be helpful to shift resources
especially to those OST patients, which require more
psychosocial support. It would, however, be unrealistic
to expect that a case-by-case allocation of OST-related
psychosocial care will result in a substantial improve-
ment of the overall provision in Germany. In general,
there is a lack of long-term data on the effectiveness of
different psychosocial interventions and their utilization
in the context of OST in Germany [8].Due to the relatively high average age of OST physi-
cians [12], almost one-third of active OST physicians in
the present sample are expected to retire within the next
decade. Especially rural areas will then face a further ag-
gravated situation of existing shortcomings and gaps in
OST provision [12,15]. One option to compensate for
the decrease in OST treatment resources could be to ex-
pand existing OST capacity into larger specialised substi-
tution treatment centres (SSCs) and to allocate more
patients to these units. Statistics of the German Federal
Institute for Drugs and Medical Devices for the years
2006 to 2011 already indicate such a trend towards lar-
ger treatment centres. In 2011, half of all OST patients
were treated in 15% of all OST treatment units [11].
However, a tendency towards the utilization of larger
SSCs also has potential limitations. First, not all opiate
addicts are attracted to specialised drug treatment cen-
tres and prefer OST care to be provided by a local GP
[15]. Second, a tendency towards larger and concen-
trated treatment centres would also affect the OST avail-
ability in rural areas, as SSCs are mainly located in
urban areas, and might therefore result in further geo-
graphic disparities in health care availability and clinical
outcomes, and thus undermine the defined aims of OST
in Germany. Furthermore, compared to SSCs, most GPs
in Germany provide OST mainly to a limited number of
patients within their general health care practice. These
GPs may have limited time and space, or may not even
want to provide OST to more patients. Interview data
from former and current OST prescribers in Australia
indicated that the willingness of GP’s to provide OST
might be influenced by their perceived ability to control
the number of OST patients [33]. In Germany, limited
care resources and capacity required to integrate OST into
their practice were found to be a main reason for the sus-
pension of OST care among those who completely termi-
nated the provision of OST services [15]. In the past, the
relatively large number of GPs involved in OST care en-
sured a high diversification and OST coverage in Germany;
such office-based approaches were found to be an effective
facilitator for OST availability and utilization [34].
The present survey features some potential methodo-
logical limitations, including potential issues in regards
to sampling. The study’s response rate of 25.5% was
quite low, and thus may have introduced the possibility
of selection bias into the responses received. In addition,
the study relied on self-report data, none of which were
independently verified; factors like social desirability may
have influenced the content of responses, although the
measures taken to protect the study participants’ identity
(e.g. anonymity) can reasonably be expected to prevent
such effects. Furthermore, the participants in the present
survey were more likely those specialised in OST, as the
proportion of large treatment centres represented was
Schulte et al. Substance Abuse Treatment, Prevention, and Policy 2013, 8:26 Page 9 of 10
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sample of OST treatment units by Wittchen et al. [29].
Therefore, results are not generalizable beyond the spe-
cific study sample.Conclusion
Our survey demonstrated the existence of structural bar-
riers in the provision of OST, and showed that these ob-
stacles considerably limit the overall provision and
uptake of OST. These structural barriers are relevant in
regards to the key fact that the majority of opiate addicts
in Germany still remain out of treatment, either by
choice or due to limited treatment access [10,15]. The
impact of the current structural conditions for OST care
on physicians’ decisions to provide OST is notably
strong: in the recent survey by Stöver et al., 82% of the
physicians licensed for but not actively providing OST,
reported that they had provided OST previously. The
majority had terminated OST due to the difficult experi-
ences with the existent regulatory framework [15].
Innovative approaches to overcome the identified
structural barriers are needed and should involve mean-
ingful adjustments to the legal and regulatory framework
for OST in Germany. Recent revisions to the regulations
for the prescription of narcotics might be helpful to en-
sure a continuous provision of OST in cases were OST
physicians are not acutely available. However, to further
improve current OST conditions, general revisions of also
the philosophical scope of the present OST regulations
are required, as the categorical abstinence-orientation of
OST in Germany increases the risk of premature termin-
ation of OST as well as patient mortality [7,8]. While some
described systemic barriers (i.e. lack of training, lack of
support services, adequate financial compensation) from
studies conducted outside of Germany are comparable
to our findings [35-38], our study identified strict legal
regulations as a principal structural barrier for OST in
Germany.
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